SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : A Biotech Bash - Recs and Wrecks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: r. peter Dale who wrote (44)8/27/1997 9:05:00 AM
From: EZLibra   of 171
 
Techniclone is preparing to launch the Tumor Necrosis Therapy (TNT) trials and wants consistency from Phasa I-Phase III. Changing the protocol from salvage therapy to front line treatment is probably what delayed the NonHodgkins Phase III so long. TNT has delivered other agents (liposomes, toxol) successfully but radiation has proven to be the most efficacious. The collaboration with PSI has affirmed this.

In human trials in China sponsored by Brilliance Pharmaceuticals and the Norris Cancer Center at the University of Southern California nine cancers in more than 40 terminal patients have been successfully treated, including complete remissions. A large Phase III for brain cancer (glioblastoma) is expected to initiate in China this fall.

TNT is about a third of TCLN's weapons against cancer, each of which is synergistic. from the press release;

Techniclone Corporation's most advanced drug development program is I-131 LYM-1 (Oncolym), a non-Hodgkin's B-cell lymphoma therapy product currently being studied in a multi-center Phase II/III clinical trial. The Company's world leadership in Collateral Targeting Agents also includes the following technologies: Tumor Necrosis Therapy (TNT), an innovative pharmaceutical compound that has the potential to destroy large tumors at the necrotic (dead) core without damaging surrounding healthy tissue; Vasopermeation Enhancing Agents (VEAs), a technology which targets tumor vessels with vasoactive agents (molecules that cause tissues to become temporarily permeable) and causes enhanced levels of drug and isotope uptake within a tumor; and Vascular Targeting Agents (VTAs), a pharmaceutical compound targeting the capillaries and vessels inside a tumor to deliver a clot-inducing drug, potentially causing the tumor to be ``starved'' of vital oxygen and nutrients necessary for its survival. The Company plans to initiate Phase I/II clinical trials for TNT in the U.S. in late 1997, with trials in Europe to follow shortly thereafter.

Thanks for asking, Peter. Davis
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News